ClinicalTrials.gg
CompletedNCT03759366Updated Dec 11, 2024Results posted

A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

A Phase 3 interventional study of Eculizumab in Myasthenia Gravis, Myasthenia Gravis, Juvenile Form and Myasthenia Gravis, Generalized, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 11 sites in 2 countries. Per ClinicalTrials.gov, last updated 2024-12-11.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Myasthenia Gravis by AstraZeneca — 8 open to participants now, 11 under way, 4 of them phase 3. Myasthenia Gravis · AstraZeneca.

Enrollment
10th of 13
12 · median 20
Started
2018
the only one that year
Phase 3
9 of 19
2 open now
Registered
4th of 19
by date

Among the 19 studies in Myasthenia Gravis by AstraZeneca, this one is the 10th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2018, is one of 9 in phase 3, and was the 4th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 144 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

8 of the 19 studies in Myasthenia Gravis by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Myasthenia Gravis by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of eculizumab in the treatment of pediatric refractory gMG based on change from Baseline in the Quantitative Myasthenia Gravis (QMG) score for disease severity.

Read the detailed description

The study will consist of an up to 4-week Screening Period, 26-week Primary Evaluation Treatment Period, an additional (up to) to 208-week Extension Period, and an 8-week Safety Follow-up Period.

03

Conditions studied

  • Myasthenia Gravis
  • Myasthenia Gravis, Juvenile Form
  • Myasthenia Gravis, Generalized

Browse trials for

Keywords

  • Myasthenia Gravis
  • Myasthenia Gravis, Generalized
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female pediatric participants 6 to \<18 years of age at time of assent/consent.
  • Vaccinated against Neisseria meningitidis.
  • Documented vaccination against Haemophilus influenzae and Streptococcus pneumoniae infections prior to dosing as per local and country specific immunization guidelines for the appropriate age group.
  • Diagnosis of MG confirmed by positive serologic test for anti-acetylcholine receptor antibodies at Screening, and 1 of the following: (a) history of abnormal neuromuscular transmission test demonstrated by single-fiber electromyography or repetitive nerve stimulation; (b) history of positive anticholinesterase test (for example, edrophonium chloride or neostigmine test); or (c) participant demonstrated improvement in MG signs on oral acetylcholinesterase inhibitors, as assessed by the Investigator.
  • Presence of gMG, defined as participants with gMG who have 1 or more of the following: (a) failed treatment ≥1 year with at least 1 therapies (IST), defined as follows: (1) persistent weakness with impairment of activities of daily living; (2) myasthenia gravis (MG) exacerbation and/or crisis while on treatment; or (3) intolerance to ISTs due to side effect or comorbid condition(s). (b) Require maintenance plasma exchange (PE) or intravenous immunoglobulin (IVIg) to control symptoms; and/or (c) in the opinion of the Investigator, MG poses a significant functional burden despite current MG treatment.
  • MGFA Clinical Classification of Class II to IV at Screening.
  • In patients aged 12 to 18 years, QMG total score ≥ 12 at Screening; in patients aged 6 to 11 years, no minimum QMG is required for inclusion; however, patients must have documented limb weakness in at least one limb.
  • All MG-specific treatment has been administered at a stable dosing regimen of adequate duration prior to Screening.

Exclusion criteria

Exclusion Criteria:

  • Parent or legal guardian is an Alexion employee.
  • Any active or untreated thymoma. History of thymic carcinoma or thymic unless deemed cured by adequate treatment with no evidence of recurrence for ≥5 years before Screening.
  • History of thymectomy within 12 months prior to Screening.
  • Are pregnant or lactating.
  • Any unresolved acute, or chronic, systemic bacterial or other infection, which is in the opinion of the Investigator and has not been treated with appropriate antibiotics.
  • Use of PE within 4 weeks prior to first dose.
  • Use of rituximab within 6 months prior to first dose.
  • Patients who are under 15 kg and are receiving maintenance IVIg.
  • Participation in another interventional treatment study or use of any experimental therapy within 30 days before initiation of study drug on Day 1 in this study or within 5 half-lives of that product, whichever is greater.
  • Have previously received treatment with eculizumab or other complement inhibitors.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Eculizumab Intravenous (IV) Infusion

    In the Primary Evaluation Treatment Period (26 weeks), eculizumab will be administered weekly during the initial induction phase and every 2 weeks during the maintenance phase. In the Extension Period (up to 208 weeks), participants will continue to receive eculizumab every 2 weeks. Eculizumab will be administered at doses of 300, 600, 900, or 1200 milligrams (mg), based on the participant's current body weight.

    Drug: Eculizumab

Interventions

  • Eculizumab will be administered by IV infusion.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the QMG Total Score at Week 26 Regardless of Rescue Treatment

    The QMG scoring system consists of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item). Each item is graded from 0 to 3, (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The range of total QMG score is 0 to 39, with higher scores indicating more severe disease.

    Time frame: Baseline, Week 26

Secondary outcomes

  1. Change From Baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) Total Score at Week 26 Regardless of Rescue Treatment

    The MG-ADL is an 8-point questionnaire that focuses on relevant symptoms and functional performance of activities of daily living in participants with myasthenia gravis (MG). The 8 items of the MG-ADL are derived from symptom-based components of the original 13-item QMG to assess disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. In this functional status instrument, each response is graded from 0 (normal) to 3 (most severe). The range of total MG-ADL score is 0 to 24, with higher scores indicating more severe disease.

    Time frame: Baseline, Week 26

  2. Percentage of Participants With ≥3-Point Reduction in the MG-ADL Total Score With No Rescue Treatment

    The MG-ADL is an 8-point questionnaire that focuses on relevant symptoms and functional performance of activities of daily living in participants with MG. The 8 items of the MG-ADL are derived from symptom-based components of the original 13-item QMG to assess disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. In this functional status instrument, each response is graded from 0 (normal) to 3 (most severe). The range of total MG-ADL score is 0 to 24, with higher scores indicating more severe disease.

    Time frame: Week 26

  3. Percentage of Participants With ≥3-Point Reduction in the MG-ADL Total Score Regardless of Rescue Treatment

    The MG-ADL is an 8-point questionnaire that focuses on relevant symptoms and functional performance of activities of daily living in participants with MG. The 8 items of the MG-ADL are derived from symptom-based components of the original 13-item QMG to assess disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. In this functional status instrument, each response is graded from 0 (normal) to 3 (most severe). The range of total MG-ADL score is 0 to 24, with higher scores indicating more severe disease.

    Time frame: Week 26

  4. Percentage of Participants With ≥5-Point Reduction in the QMG Total Score With No Rescue Treatment

    The QMG scoring system consists of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item). Each item is graded from 0 to 3, (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The range of total QMG score is 0 to 39, with higher scores indicating more severe disease.

    Time frame: Week 26

  5. Percentage of Participants With ≥5-Point Reduction in the QMG Total Score Regardless of Rescue Treatment

    The QMG scoring system consists of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item). Each item is graded from 0 to 3, (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The range of total QMG score is 0 to 39, with higher scores indicating more severe disease.

    Time frame: Week 26

  6. Change From Baseline in the Myasthenia Gravis Composite (MGC) Scale Total Score at Week 26 Regardless of Rescue Treatment

    The MGC is a validated assessment tool for measuring clinical status of participants with MG. The MGC assesses 10 important functional areas most frequently affected by MG: ocular (2 items), facial (1 item), bulbar (3 items), respiratory (1 item), axial (1 item), and gross motor (2 items). The scales are weighted for clinical significance that incorporates patient-reported outcomes. The MGC total score ranges from 0 to 50, with lower scores indicating less functional impairment and higher scores indicating greater functional impairment.

    Time frame: Baseline, Week 26

  7. Change From Baseline in the European Quality of Life 5-Dimension Youth Version (EQ-5D-Y) Visual Analogue Scale (VAS) Score at Week 26 Regardless of Rescue Treatment

    The EQ-5D-Y is a reliable and validated survey of health status in 5 areas: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each of which is completed by the participant for participants ≥12 years of age (at time of assessment) and completed by the participant's caregiver or with caregiver assistance for participant \<12 years of age. Each area has 3 levels: Level 1 (no problems), Level 2 (some problems), and Level 3 (extreme problems). The EQ visual analogue scale (VAS) records the participant's self-rated health on a vertical, 20-centimeter VAS where the endpoints are labelled 'Best imaginable health state, marked as 100' and 'Worst imaginable health state, marked as 0'.

    Time frame: Baseline, Week 26

  8. Change From Baseline in the Neurological Quality of Life-Fatigue Questionnaire (Neuro-QoL Pediatric Fatigue) Total Score at Week 26 Regardless of Rescue Treatment

    The Neuro-QoL Pediatric Fatigue questionnaire is a reliable and validated brief 11-item survey of fatigue, completed by the participant for participants ≥12 years of age (at time of assessment) and completed by the participant's caregiver or with caregiver assistance for participants \<12 years of age. Each item was scored on a scale of 1 to 5 (1=Not at all, 2=A little bit, 3=Somewhat, 4=Quite a bit, 5=Very much). Total score is the sum of each item's score and it ranges from 11 to 55. Higher scores indicate greater fatigue and greater impact of MG on activities.

    Time frame: Baseline, Week 26

  9. Number of Participants in Each Category of the Myasthenia Gravis Foundation of America Post-Intervention Status (MGFAPIS) Regardless of Rescue Treatment at Week 26

    The MG clinical state (improved, unchanged, and worse) was assessed using the MGFAPIS.

    Time frame: Week 26

  10. Percentage of Participants With Clinical Deteriorations, Myasthenic Crises, and Rescue Therapy Use

    Rescue therapy (for example, high dose corticosteroid, plasma exchange, or intravenous immunoglobulin) was to be allowed when a participant experienced clinical deterioration. Clinical deterioration was defined as follows: Participants who experienced an MG crisis, which was defined as weakness due to MG that was severe enough to necessitate intubation or to delay extubation following surgery; or, Significant symptomatic worsening that required rescue medication in the opinion of the Investigator; or, Participants for whom the Investigator believed that the participants' health was in jeopardy if rescue therapy was not given.

    Time frame: Baseline up to Week 26

  11. Pharmacokinetics (PK): Serum Concentration Of Eculizumab

    Time frame: 24 hours postdose on Day 1; predose and 60 minutes postdose at Week 12; predose at Week 26

  12. Pharmacodynamics (PD): Serum Free Complement Component 5 Concentrations

    Time frame: Baseline; 24 hours postdose on Day 1; predose and 60 minutes postdose at Week 12; predose at Week 26

  13. PD: Percentage of Hemolysis (In Vitro Assay)

    Time frame: Baseline; 24 hours postdose on Day 1; predose and 60 minutes postdose at Week 12; predose at Week 26

  14. Change From Baseline in the QMG Total Score at Week 52 Regardless of Rescue Treatment

    The QMG scoring system consists of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item). Each item is graded from 0 to 3, (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The range of total QMG score is 0 to 39, with higher scores indicating more severe disease.

    Time frame: Baseline, Week 52

07

Results

Posted Aug 25, 2022

Participant flow

The study included a Primary Evaluation Treatment Period of 26 weeks, an Extension Period of up to an additional 208 weeks, and a Follow-up Period of 8 weeks.

Primary Evaluation Period (26 Weeks)
Participant flow — Primary Evaluation Period (26 Weeks)
MilestoneEculizumab
Started11
Received at least 1 dose of study drug11
Completed10
Not completed1
Withdrew: Physician decision1
Extension Period (Up to 208 Weeks)
Participant flow — Extension Period (Up to 208 Weeks)
MilestoneEculizumab
Started10
Received at least 1 dose of study drug10
Completed2
Not completed8
Withdrew: Physician decision1
Withdrew: Lost to follow-up1
Withdrew: Participant transitioned to ultomiris2
Withdrew: Participant transitioned to soliris1
Withdrew: Participant transferred to another study1
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryChange From Baseline in the QMG Total Score at Week 26 Regardless of Rescue Treatment

The QMG scoring system consists of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item). Each item is graded from 0 to 3, (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The range of total QMG score is 0 to 39, with higher scores indicating more severe disease.

Time frame:
Baseline, Week 26
Reported as:
Mean · units on a scale
Change From Baseline in the QMG Total Score at Week 26 Regardless of Rescue Treatment
units on a scaleEculizumab
Change From Baseline in the QMG Total Score at Week 26 Regardless of Rescue Treatment-6.1 ± 4.56
Statistical analysis
  • Eculizumab · Repeated Measures Model · p = 0.0004 · Least square mean: -5.8 · 95% CI -8.40 to -3.13The least square mean change from baseline in QMG total score at Week 26 was calculated.
SecondaryChange From Baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) Total Score at Week 26 Regardless of Rescue Treatment

The MG-ADL is an 8-point questionnaire that focuses on relevant symptoms and functional performance of activities of daily living in participants with myasthenia gravis (MG). The 8 items of the MG-ADL are derived from symptom-based components of the original 13-item QMG to assess disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. In this functional status instrument, each response is graded from 0 (normal) to 3 (most severe). The range of total MG-ADL score is 0 to 24, with higher scores indicating more severe disease.

Time frame:
Baseline, Week 26
Reported as:
Mean · units on a scale
Change From Baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) Total Score at Week 26 Regardless of Rescue Treatment
units on a scaleEculizumab
Change From Baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) Total Score at Week 26 Regardless of Rescue Treatment-2.5 ± 1.78
SecondaryPercentage of Participants With ≥3-Point Reduction in the MG-ADL Total Score With No Rescue Treatment

The MG-ADL is an 8-point questionnaire that focuses on relevant symptoms and functional performance of activities of daily living in participants with MG. The 8 items of the MG-ADL are derived from symptom-based components of the original 13-item QMG to assess disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. In this functional status instrument, each response is graded from 0 (normal) to 3 (most severe). The range of total MG-ADL score is 0 to 24, with higher scores indicating more severe disease.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With ≥3-Point Reduction in the MG-ADL Total Score With No Rescue Treatment
percentage of participantsEculizumab
Percentage of Participants With ≥3-Point Reduction in the MG-ADL Total Score With No Rescue Treatment50.0 ± 18.7
SecondaryPercentage of Participants With ≥3-Point Reduction in the MG-ADL Total Score Regardless of Rescue Treatment

The MG-ADL is an 8-point questionnaire that focuses on relevant symptoms and functional performance of activities of daily living in participants with MG. The 8 items of the MG-ADL are derived from symptom-based components of the original 13-item QMG to assess disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. In this functional status instrument, each response is graded from 0 (normal) to 3 (most severe). The range of total MG-ADL score is 0 to 24, with higher scores indicating more severe disease.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With ≥3-Point Reduction in the MG-ADL Total Score Regardless of Rescue Treatment
percentage of participantsEculizumab
Percentage of Participants With ≥3-Point Reduction in the MG-ADL Total Score Regardless of Rescue Treatment50.0 ± 18.7
SecondaryPercentage of Participants With ≥5-Point Reduction in the QMG Total Score With No Rescue Treatment

The QMG scoring system consists of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item). Each item is graded from 0 to 3, (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The range of total QMG score is 0 to 39, with higher scores indicating more severe disease.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With ≥5-Point Reduction in the QMG Total Score With No Rescue Treatment
percentage of participantsEculizumab
Percentage of Participants With ≥5-Point Reduction in the QMG Total Score With No Rescue Treatment70.0 ± 34.8
SecondaryPercentage of Participants With ≥5-Point Reduction in the QMG Total Score Regardless of Rescue Treatment

The QMG scoring system consists of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item). Each item is graded from 0 to 3, (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The range of total QMG score is 0 to 39, with higher scores indicating more severe disease.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With ≥5-Point Reduction in the QMG Total Score Regardless of Rescue Treatment
percentage of participantsEculizumab
Percentage of Participants With ≥5-Point Reduction in the QMG Total Score Regardless of Rescue Treatment70.0 ± 34.8
SecondaryChange From Baseline in the Myasthenia Gravis Composite (MGC) Scale Total Score at Week 26 Regardless of Rescue Treatment

The MGC is a validated assessment tool for measuring clinical status of participants with MG. The MGC assesses 10 important functional areas most frequently affected by MG: ocular (2 items), facial (1 item), bulbar (3 items), respiratory (1 item), axial (1 item), and gross motor (2 items). The scales are weighted for clinical significance that incorporates patient-reported outcomes. The MGC total score ranges from 0 to 50, with lower scores indicating less functional impairment and higher scores indicating greater functional impairment.

Time frame:
Baseline, Week 26
Reported as:
Mean · units on a scale
Change From Baseline in the Myasthenia Gravis Composite (MGC) Scale Total Score at Week 26 Regardless of Rescue Treatment
units on a scaleEculizumab
Change From Baseline in the Myasthenia Gravis Composite (MGC) Scale Total Score at Week 26 Regardless of Rescue Treatment-9.4 ± 5.91
SecondaryChange From Baseline in the European Quality of Life 5-Dimension Youth Version (EQ-5D-Y) Visual Analogue Scale (VAS) Score at Week 26 Regardless of Rescue Treatment

The EQ-5D-Y is a reliable and validated survey of health status in 5 areas: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each of which is completed by the participant for participants ≥12 years of age (at time of assessment) and completed by the participant's caregiver or with caregiver assistance for participant \<12 years of age. Each area has 3 levels: Level 1 (no problems), Level 2 (some problems), and Level 3 (extreme problems). The EQ visual analogue scale (VAS) records the participant's self-rated health on a vertical, 20-centimeter VAS where the endpoints are labelled 'Best imaginable health state, marked as 100' and 'Worst imaginable health state, marked as 0'.

Time frame:
Baseline, Week 26
Reported as:
Mean · units on a scale
Change From Baseline in the European Quality of Life 5-Dimension Youth Version (EQ-5D-Y) Visual Analogue Scale (VAS) Score at Week 26 Regardless of Rescue Treatment
units on a scaleEculizumab
Change From Baseline in the European Quality of Life 5-Dimension Youth Version (EQ-5D-Y) Visual Analogue Scale (VAS) Score at Week 26 Regardless of Rescue Treatment23.5 ± 23.34
SecondaryChange From Baseline in the Neurological Quality of Life-Fatigue Questionnaire (Neuro-QoL Pediatric Fatigue) Total Score at Week 26 Regardless of Rescue Treatment

The Neuro-QoL Pediatric Fatigue questionnaire is a reliable and validated brief 11-item survey of fatigue, completed by the participant for participants ≥12 years of age (at time of assessment) and completed by the participant's caregiver or with caregiver assistance for participants \<12 years of age. Each item was scored on a scale of 1 to 5 (1=Not at all, 2=A little bit, 3=Somewhat, 4=Quite a bit, 5=Very much). Total score is the sum of each item's score and it ranges from 11 to 55. Higher scores indicate greater fatigue and greater impact of MG on activities.

Time frame:
Baseline, Week 26
Reported as:
Mean · units on a scale
Change From Baseline in the Neurological Quality of Life-Fatigue Questionnaire (Neuro-QoL Pediatric Fatigue) Total Score at Week 26 Regardless of Rescue Treatment
units on a scaleEculizumab
Change From Baseline in the Neurological Quality of Life-Fatigue Questionnaire (Neuro-QoL Pediatric Fatigue) Total Score at Week 26 Regardless of Rescue Treatment-7.9 ± 7.37
SecondaryNumber of Participants in Each Category of the Myasthenia Gravis Foundation of America Post-Intervention Status (MGFAPIS) Regardless of Rescue Treatment at Week 26

The MG clinical state (improved, unchanged, and worse) was assessed using the MGFAPIS.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Number of Participants in Each Category of the Myasthenia Gravis Foundation of America Post-Intervention Status (MGFAPIS) Regardless of Rescue Treatment at Week 26
ParticipantsEculizumab
Improved10
Unchanged0
Worse0
SecondaryPercentage of Participants With Clinical Deteriorations, Myasthenic Crises, and Rescue Therapy Use

Rescue therapy (for example, high dose corticosteroid, plasma exchange, or intravenous immunoglobulin) was to be allowed when a participant experienced clinical deterioration. Clinical deterioration was defined as follows: Participants who experienced an MG crisis, which was defined as weakness due to MG that was severe enough to necessitate intubation or to delay extubation following surgery; or, Significant symptomatic worsening that required rescue medication in the opinion of the Investigator; or, Participants for whom the Investigator believed that the participants' health was in jeopardy if rescue therapy was not given.

Time frame:
Baseline up to Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Deteriorations, Myasthenic Crises, and Rescue Therapy Use
percentage of participantsEculizumab
Clinical Deterioration9.1
MG Crisis9.1
Requiring Rescue Therapy9.1
SecondaryPharmacokinetics (PK): Serum Concentration Of Eculizumab
Time frame:
24 hours postdose on Day 1; predose and 60 minutes postdose at Week 12; predose at Week 26
Reported as:
Mean · micrograms (μg)/milliliter (mL)
Pharmacokinetics (PK): Serum Concentration Of Eculizumab
micrograms (μg)/milliliter (mL)Eculizumab
Day 1, 24 hours postdose359.6 ± 105.18
Week 12, Predose382.8 ± 159.57
Week 12, 60 minutes postdose910.5 ± 277.29
Week 26, Predose433.9 ± 171.85
SecondaryPharmacodynamics (PD): Serum Free Complement Component 5 Concentrations
Time frame:
Baseline; 24 hours postdose on Day 1; predose and 60 minutes postdose at Week 12; predose at Week 26
Reported as:
Mean · μg/mL
Pharmacodynamics (PD): Serum Free Complement Component 5 Concentrations
μg/mLEculizumab
Baseline172.7 ± 34.52
Day 1, 24 hours postdose0.0 ± 0.01
Week 12, Predose0.0 ± 0.01
Week 12, 60 minutes postdose0.0 ± 0.01
Week 26, Predose0.0 ± 0.02
SecondaryPD: Percentage of Hemolysis (In Vitro Assay)
Time frame:
Baseline; 24 hours postdose on Day 1; predose and 60 minutes postdose at Week 12; predose at Week 26
Reported as:
Mean · percentage of hemolysis
PD: Percentage of Hemolysis (In Vitro Assay)
percentage of hemolysisEculizumab
Baseline105.8 ± 14.15
Day 1, 24 hours postdose1.1 ± 2.01
Week 12, Predose1.8 ± 4.67
Week 12, 60 minutes postdose0.2 ± 0.45
Week 26, Predose0.5 ± 1.29
SecondaryChange From Baseline in the QMG Total Score at Week 52 Regardless of Rescue Treatment

The QMG scoring system consists of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item). Each item is graded from 0 to 3, (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The range of total QMG score is 0 to 39, with higher scores indicating more severe disease.

Time frame:
Baseline, Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the QMG Total Score at Week 52 Regardless of Rescue Treatment
units on a scaleEculizumab
Change From Baseline in the QMG Total Score at Week 52 Regardless of Rescue Treatment-4.9 ± 4.26
Statistical analysis
  • Eculizumab · Repeated Measures Model · p = 0.0033 · Least square mean: -4.3 · 95% CI -6.93 to -1.65The least square mean change from baseline in QMG total score at Week 52 was calculated.

Adverse events

Collected over From date of first dose (Day 1) through 8 weeks after last dose (4 years and 7 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eculizumab0/11 (0%)4/11 (36.4%)11/11 (100%)
Most frequent serious events
Most frequent serious events
EventEculizumab
PyrexiaGeneral disorders1/11
Peritonsillar abscessInfections and infestations1/11
Myasthenia gravisNervous system disorders1/11
Myasthenia gravis crisisNervous system disorders1/11
Suicide attemptPsychiatric disorders1/11
Most frequent other events
Showing 10 of 101
Most frequent other events
EventEculizumab
NasopharyngitisInfections and infestations6/11
HeadacheNervous system disorders4/11
FatigueGeneral disorders3/11
Upper respiratory tract infectionInfections and infestations3/11
Pain in extremityMusculoskeletal and connective tissue disorders3/11
Abdominal painGastrointestinal disorders3/11
Oropharyngeal painRespiratory, thoracic and mediastinal disorders3/11
PyrexiaGeneral disorders3/11
COVID-19Infections and infestations2/11
MyalgiaMusculoskeletal and connective tissue disorders2/11

Baseline characteristics

Safety Analysis Set: all participants who received at least 1 dose of eculizumab.

Age, Continuous
Age, Continuous(years)Eculizumab
Mean14.8 ± 1.78
Sex: Female, Male
Sex: Female, Male(Participants)Eculizumab
Female9
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Eculizumab
Hispanic or Latino2
Not Hispanic or Latino9
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Eculizumab
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American5
White2
More than one race0
Unknown or Not Reported1
Quantitative Myasthenia Gravis (QMG) Total Score
Quantitative Myasthenia Gravis (QMG) Total Score(units on a scale)Eculizumab
Mean16.7 ± 5.64
08

Study locations

11 sites
  • Research Site
    Los Angeles, California 90078, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Columbia, Missouri 65201, United States
  • Research Site
    Chapel Hill, North Carolina 27599, United States
  • Research Site
    Akron, Ohio 44308, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Iruma-Gun, 350-0495, Japan
  • Research Site
    Itabashi-ku, 173-0003, Japan
  • Research Site
    Shinjuku-ku, 162-8666, Japan
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Jan 2022, 36 months.

Results were first posted in Aug 2022, 7 months after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 36 months is above that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2018
First posted
Nov 30, 2018
StartActual
Dec 28, 2018
Primary completionActual
Jan 6, 2022
CompletionActual
Nov 6, 2023
Results first posted
Aug 25, 2022
Last update
Dec 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03759366
Responsible party
Sponsor
First posted
Nov 30, 2018
Start date
Dec 28, 2018
Primary completion
Jan 6, 2022
Completion
Nov 6, 2023
Results posted
Aug 25, 2022
Last update
Dec 11, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion